Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology

MENLO PARK, Calif. and CAMBRIDGE, United KingdomDec. 21, 2020 /PRNewswire/ — Gamma Biosciences, a life sciences tools platform created by KKR, today announced a licensing agreement between Astrea Bioseparations, a leader in affinity chromatography and bioseparations, and Avacta, a developer of innovative cancer therapies and diagnostics based on proprietary Affimer® and preCISION™ platforms. The licensing agreement gives Astrea access to the Affimer technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include best-in-class chemical and biological platforms for customer development programs.

“Affimer reagents are high-performance proteinaceous ligands that have been engineered for a wide range of applications as superior alternatives to antibody-based ligands. They can be used to selectively bind difficult targets, even where antibodies and aptamers have shown limitations. In combination with our proven Mimetic Ligand® chemical ligand libraries, the Affimer ligand platform significantly expands our capacity to discover, develop and deliver custom affinity adsorbents for purification of biotherapeutics and advanced therapies,” said Dr. Steve Burton, CEO of Astrea Bioseparations.

“Avacta chose to partner with Astrea based on its 35-year history of developing customized chromatography resins and affinity ligands, and a shared passion for advancing medicine. The license agreement includes an option that gives Astrea the ability to secure exclusive access to the Affimer technology for applications in bioprocessing. We look forward to partnering with the capable team at Astrea to enable new advances in the industry,” said Alastair Smith, CEO at Avacta.

“This agreement is a step forward as Astrea continues to redefine what is possible with affinity chromatography aligned with meticulous customer support. The license enables Astrea to provide an almost limitless repertoire of selective binding ligands with the ability to attach these to a variety of high-performance chromatography substrates, from PuraBead® near-monodisperse agarose beads to the NanoPareilSM high-surface-area nano-fiber membranes,” said Phil Vanek, CTO at Gamma Biosciences.

Initial development work will focus on viral vectors and custom projects for third parties, leveraging the benefits of ligand diversity, stability, favorable elution conditions, and reproducible performance to address these traditionally challenging categories. The Astrea Bioseparations team expects to begin development of new products based on the technology early in 2021. Custom project inquiries are welcome and may be directed to Bruce Dawson at Astrea ([email protected]).

About Gamma Biosciences
Gamma Biosciences is a life sciences tools platform created by KKR. Gamma’s mission is to build a leading player in next-generation bioprocessing for advanced therapies by acquiring high-potential businesses with outstanding technology and accelerating their growth. For more information about Gamma Biosciences, please visit www.gammabiosciences.com.

About Astrea Bioseparations      
Astrea Bioseparations Ltd. (formerly Prometic Bioseparations Ltd) provides bioseparation products to the pharmaceutical and biotech markets, including chromatography adsorbents, custom adsorbent discovery and development services and pre-packed chromatography columns and column hardware. A wholly owned subsidiary of Gamma Biosciences, a life sciences tools platform supported by KKR, Astrea Bioseparations has R&D laboratories located at Cambridge, UK and manufacturing facilities located at the Isle of Man, British Isles, Joliette, Quebec, Canada and Stoughton, Massachusetts, USA. For more information about Astrea Bioseparations, please visit www.astreabioseparations.com.

About Avacta Group plc
Avacta is developing diagnostics and novel cancer immunotherapies based on its two proprietary platforms – Affimer® affinity reagents and pre|CISION™ tumour targeted chemotherapy. The Company’s therapeutic division, based in Cambridge UK, aims to address the lack of a durable response to current immunotherapies experienced by most patients through the combination of these two platforms. Avacta’s diagnostics business unit works with partners world-wide to develop Affimer reagents for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing an in-house pipeline of Affimer-based diagnostic assays for licensing.

For further information about Avacta please visit www.avacta.com.

For further information please contact:

Beth Willers
White Matter Communications
[email protected]